基于国际III期随机双盲安慰剂对照PANORAMA-1试验:接受≥2线治疗后使用帕比司他的多发性骨髓瘤患者报告结局
PANORAMA-1试验中,73例帕比司他联合硼替佐米和地塞米松组与74例安慰剂联合硼替佐米和地塞米松组患者完成患者报告结局评估。整体健康状况/生活质量评分在帕比司他组前24周初始下降后趋近基线并保持稳定,第48周两组无差异。作者认为患者报告结局支持在硼替佐米和地塞米松方案中加入帕比司他。
要点
- 帕比司他组整体健康状况/生活质量评分前24周初始下降,随后趋近基线并保持稳定,第48周两组无差异。
- 两组疾病症状评分均初始改善后稳定,治疗副作用评分均初始恶化后改善,帕比司他组初始恶化更明显且恢复更不明显。
- 神经毒性评分两组保持相对稳定且相似;结果为描述性分析,未进行正式统计学检验。
核心结论
- 患者报告结局支持在硼替佐米和地塞米松方案中加入帕比司他,作为一种症状有限且对患者生活质量影响有限的有效治疗选择。
研究设计与样本
- 国际III期随机双盲安慰剂对照PANORAMA-1试验的患者报告结局分析,帕比司他联合硼替佐米和地塞米松组73例,安慰剂联合硼替佐米和地塞米松组74例。
- 结果为描述性分析,未进行正式统计学检验。
主要发现
- 根据EORTC QLQ-C30,帕比司他联合硼替佐米和地塞米松组整体健康状况/生活质量评分在前24周初始下降,随后趋近基线并在接下来24周保持稳定,第48周两组间无差异。
- 根据EORTC QLQ-MY20,两组疾病症状评分均显示初始改善并随后稳定;治疗副作用评分均显示初始恶化并随后改善,帕比司他联合硼替佐米和地塞米松组初始恶化更明显且恢复更不明显。
- FACT/GOG-Neurotoxicity评分两组保持相对稳定且相似。
局限性
- 结果为描述性分析,未进行正式统计学检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48. The EORTC QLQ-Myeloma module (EORTC QLQ-MY20) demonstrated initial improvements and subsequent stabilization of disease symptom scores in both arms and initial worsening and subsequent improvement of side effects of treatment scores, with the initial worsening more pronounced and recovery less pronounced with PAN + BTZ + DEX. Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scores remained relatively stable and similar between the arms. Overall, these PRO findings support the addition of PAN to the BTZ+DEX regimen as an efficacious treatment option, with limited symptomatology and impact on patients' QoL. The reported results are based on a descriptive analysis of the data. No formal statistical tests have been performed.
引用
- Richardson PG, Schlossman RL, Roy AN, et al. Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. Br J Haematol. 2018. PMID: 29774521. doi:10.1111/bjh.15248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。